Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vogenx, Inc.

NASDAQ: VOGX · Life Sciences · 4 alerts · CIK 1903784

Share price
$14.38Close, Nov 16
Market cap
$214M
Shares outstanding
14.86MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vogenx, Inc. filings on SEC EDGAR ↗

5:24 PM ET 10-Q
Financial Results

Vogenx Q3 2026 Results: Net Loss of $4.91M, Loss Widens

Vogenx, Inc. is a clinical-stage biopharmaceutical company that has incurred significant losses since inception and expects to continue doing so for the foreseeable future. The company currently generates no revenue from product sales and requires substantial additional funding to advance its research and development programs, including its lead candidate mizagliflozin.

Key figure
Net loss $4.91M
6:48 AM ET 8-K
Financial Results

Vogenx Financial Results

Vogenx reported Q3 2026 financial results, its first as a public company following a $93.4 million IPO in August. The company ended the quarter with $82.1 million in cash and initiated its Phase 2b EMERGE study for mizagliflozin in post-bariatric hypoglycemia.

Term
Q3 2026

“Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August. The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis.”

James Green, Chief Executive Officer of Vogenx

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.